Market Overview

Why Immutep's Stock Is Trading Higher Today


Immutep (NASDAQ: IMMP) shares are trading higher on Wednesday after the company was granted a European patent for its IMP761.

Immutep is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of cancer indications.

Immutep shares traded up 9.15% to $1.79 on Wednesday at the time of publication. The stock has a 52-week high of $3.10 and a 52-week low of 53 cents.


Related Articles (IMMP)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Penny Stocks Legal